Clinical trials · New York
Alcohol Use Disorder clinical trials in New York
We’re tracking 27 recruiting alcohol use disorder studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07219966RecruitingPhase 3
Study of Brenipatide for alcohol use disorder
This trial tests an injectable medicine called brenipatide to help people with moderate-to-severe alcohol use disorder reduce or stop drinking. It is for adults who are motivated to change their drinking habits.
The Bronx, New YorkAges 18–75 - NCT05974202Recruiting
Brain stimulation and therapy for cocaine use
This study tests a combination of brain stimulation (rTMS) and talk therapy (CBT) to help people reduce cocaine use. It's for adults who want treatment and use cocaine at least once a week.
New York, New YorkAges 22–65 - NCT07219953RecruitingPhase 3
Testing brenipatide for alcohol use disorder
This study tests an experimental medicine called brenipatide to help people reduce or stop drinking. It involves getting a daily injection and completing check-ins and questionnaires over several months.
The Bronx, New YorkAges 18–75 - NCT06548490RecruitingPhase 2
Semaglutide for Opioid Use Disorder
This study tests whether a once-weekly injection of semaglutide (a GLP-1 receptor agonist) can reduce opioid use in people who are already on buprenorphine or methadone but still using opioids. It lasts about 19 weeks.
New York, New YorkAges 18–75 - NCT07216872Recruiting
Deep TMS to reduce heavy drinking in alcohol use disorder
This trial tests a non-invasive brain stimulation device (Deep TMS) to help people with alcohol use disorder reduce or stop heavy drinking. It uses magnetic pulses to target brain areas linked to addiction.
Woodbury, New YorkAges 18–86 - NCT03667846RecruitingPhase 2
Biomarker-guided treatment for drinking and PTSD symptoms
This Phase 2 study tests whether blood/brain “biomarkers” can help choose a treatment plan for people who have alcohol use disorder and PTSD. The goal is to improve outcomes related to drinking and PTSD symptoms compared with a standard approach.
New York, New YorkAges 18–70 - NCT04197921Recruiting
Brain-focused ultrasound for opioid addiction-related substance use
This trial studies Exablate, a non-surgical brain treatment that aims to change activity in a specific brain area involved in cravings and substance use. It is meant for people in structured opioid or substance use treatment who are currently abstaining from opioids and other illicit drugs.
New York, New YorkAges 18–60 - NCT05943171Recruiting
App-based CBT for substance dependence and relationship aggression
This study tests an app-guided version of CBT (a structured talk-therapy approach) against standard CBT to help people with substance dependence and recent verbal aggression in an intimate relationship. You may be screened to see if you fit both the substance use and relationship aggression parts of the trial.
Rochester, New YorkAges 18–65 - NCT07420283RecruitingPhase 2
Study of Brenipatide for opioid use disorder
This trial tests a new medicine called Brenipatide for people with opioid use disorder who are already taking buprenorphine but still occasionally use non-prescribed opioids. It aims to see if the study drug can help reduce opioid use.
New York, New YorkAges 18–75 - NCT05450718RecruitingPhase 4
Low-dose buprenorphine start for opioid use disorder
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
The Bronx, New YorkAges 18 years+ - NCT05452772RecruitingPhase 2
Psilocybin plus niacin to help quit smoking
This Phase 2 study tests whether a psilocybin “session” with niacin can help people quit smoking. It’s for adults who smoke daily and want to quit but have tried and struggled before.
New York, New YorkAges 21 years+ - NCT05011266RecruitingPhase 2/Phase 3
Buprenorphine plus naltrexone shot to prevent opioid relapse
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
New York, New YorkAges 18–65 - NCT06796062RecruitingPhase 2
Psilocybin for opioid use disorder
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
The Bronx, New YorkAges 18–65 - NCT06349083RecruitingPhase 2
Psilocybin-assisted treatment for alcohol use disorder
This study tests whether psilocybin, a psychedelic drug, combined with therapy can help people reduce or stop drinking. It aims to understand how psilocybin affects the brain and behavior in people with alcohol use disorder.
New York, New YorkAges 18–65 - NCT04084860RecruitingPhase 2
Brief medicine trial to help reduce heavy alcohol drinking
This Phase 2 study tests a brief medication approach meant to reduce “problem drinking.” It may help people cut back or stop alcohol use by adjusting brain signaling related to drinking cravings and urges.
New York, New YorkAges 21–70 - NCT06319872RecruitingPhase 1
Study of disulfiram for vision in retinal degeneration
This trial tests whether disulfiram, a drug used for alcohol use disorder, can improve vision in people with retinal degeneration. You must have an alcohol use diagnosis and agree to avoid alcohol for 6 months.
Rochester, New YorkAges 18 years+ - NCT06793488RecruitingEarly Phase 1
Anxiety and alcohol use disorder treatment study
This study tests whether a medication called disulfiram (Antabuse) can help people with alcohol use disorder (AUD) feel less anxious when they stop drinking. Researchers will also use brain scans (MRI) to look at how the brain changes during early abstinence.
New York, New YorkAges 21–55 - NCT06853314Recruiting
PrEP for women with past legal or child welfare involvement
This trial tests a program to help women who have had contact with the criminal legal system or child protective services get and stay on PrEP (a daily pill that prevents HIV). The study also looks at how to support women who have experienced intimate partner violence or risky drinking.
New York, New YorkAges 18 years+ - NCT07184983Recruiting
Brain stimulation for cannabis use disorder
This study tests whether a gentle brain stimulation technique (called tDCS) can help people who want to cut down or stop using cannabis. You'll wear a headband-like device during sessions at NYU, and the study team will check in with you over time.
New York, New YorkAges 22–65 - NCT06726200RecruitingEarly Phase 1
Comparing buprenorphine formulations for fentanyl addiction
This study tests two different forms of buprenorphine (a medication for opioid addiction) to see which works better for people who use fentanyl or other strong synthetic opioids. If you are seeking treatment for opioid use, this trial may help you find the most effective option.
New York, New YorkAges 18–65 - NCT07039175RecruitingPhase 3
Helping veterans with chronic disease change smoking or drinking habits
This study tests a program to help veterans with diabetes, heart disease, or related conditions who are thinking about cutting back on smoking or alcohol. The goal is to see if the program can motivate positive changes in these habits.
Buffalo, New YorkAges 18 years+ - NCT07644052RecruitingPhase 3
A medication to ease cannabis withdrawal symptoms
This study tests whether a medication called PP-01 can help reduce cravings and uncomfortable symptoms when people stop using cannabis. If you're a heavy cannabis user who wants to quit and experiences withdrawal symptoms, this trial may help you manage the difficult transition.
New York, New YorkAges 18–55 - NCT04458545RecruitingPhase 1/Phase 2
Opioid vaccine study for adults with heroin or fentanyl use
This trial tests a vaccine made from parts designed to help the body respond to opioids (heroin or fentanyl). It is mainly for adults with moderate-to-severe opioid use disorder who are using opioids that match the study dosing needs and who are willing to do frequent visits over about a year.
New York, New YorkAges 18–59 - NCT05033028RecruitingPhase 3
Using a smartphone to support opioid addiction recovery
This Phase 3 study tests whether using smartphones can help people with opioid-use disorder stick with treatment and recover more successfully. It focuses on people starting or already in treatment using methadone or buprenorphine, with support delivered through the study app or messages.
New York, New YorkAges 18–85
Alcohol Use Disorder trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting alcohol use disorder studies listed above.
- NYU Langone Health · 6 studies
- New York State Psychiatric Institute · 4 studies
- Adams Clinical Bronx · 3 studies
- Adams Clinical Harlem
- Columbia University Irving Medical Center
- ManuMind Interventional Psychiatry
- Montefiore Medical Center
- New York University
What taking part in a alcohol use disorder study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alcohol Use Disorder trials in other states
Common questions
- Are there alcohol use disorder clinical trials in New York?
- Yes. We're currently tracking 27 recruiting alcohol use disorder studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alcohol use disorder study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alcohol use disorder trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alcohol use disorder studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.